Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$286.14
+0.9%
$278.40
$190.75
▼
$302.93
$508.07B0.26.26 million shs3.90 million shs
Lincoln National Corporation stock logo
LNC
Lincoln National
$39.65
-3.4%
$41.19
$32.18
▼
$47.67
$7.60B1.162.03 million shs1.21 million shs
Phillips 66 stock logo
PSX
Phillips 66
$239.54
-1.3%
$268.19
$127.16
▼
$299.39
$93.94B0.692.89 million shs2.71 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.89%-3.87%-1.84%+6.68%+21.54%
Lincoln National Corporation stock logo
LNC
Lincoln National
-2.45%-1.62%+3.95%-2.47%+3.00%
Phillips 66 stock logo
PSX
Phillips 66
-1.03%-7.86%-16.81%-0.40%+80.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$286.14
+0.9%
$278.40
$190.75
▼
$302.93
$508.07B0.26.26 million shs3.90 million shs
Lincoln National Corporation stock logo
LNC
Lincoln National
$39.65
-3.4%
$41.19
$32.18
▼
$47.67
$7.60B1.162.03 million shs1.21 million shs
Phillips 66 stock logo
PSX
Phillips 66
$239.54
-1.3%
$268.19
$127.16
▼
$299.39
$93.94B0.692.89 million shs2.71 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.89%-3.87%-1.84%+6.68%+21.54%
Lincoln National Corporation stock logo
LNC
Lincoln National
-2.45%-1.62%+3.95%-2.47%+3.00%
Phillips 66 stock logo
PSX
Phillips 66
-1.03%-7.86%-16.81%-0.40%+80.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.83
Moderate Buy$299.623.85% Upside
Lincoln National Corporation stock logo
LNC
Lincoln National
2.46
Hold$48.7521.34% Upside
Phillips 66 stock logo
PSX
Phillips 66
2.62
Moderate Buy$270.1211.47% Upside

Current Analyst Ratings Breakdown

Latest LNC, ABBV, and PSX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Set Price TargetOverweight$349.00
11/17/2026
Lincoln National Corporation stock logo
LNC
Lincoln National
Boost Price TargetOutperform$50.00 ➝ $51.00
11/17/2026
Phillips 66 stock logo
PSX
Phillips 66
DowngradeStrong-Buy ➝ Hold
11/16/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$325.00 ➝ $335.00
11/12/2026
Lincoln National Corporation stock logo
LNC
Lincoln National
Lower Price TargetOverweight$54.00 ➝ $53.00
11/4/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Set Price Target$315.00
11/4/2026
Phillips 66 stock logo
PSX
Phillips 66
Boost Price TargetNeutral$297.00 ➝ $302.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Reiterated RatingMarket Perform$275.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetBuy$288.00 ➝ $322.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetOverweight$300.00 ➝ $340.00
11/2/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Boost Price TargetNeutral$275.00 ➝ $295.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$66.01B7.73$15.28 per share18.88($2.57) per share-112.26
Lincoln National Corporation stock logo
LNC
Lincoln National
$18.21B0.42$8.18 per share4.91$46.58 per share0.86
Phillips 66 stock logo
PSX
Phillips 66
$136.56B0.69$14.56 per share16.64$91.02 per share2.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$5.8149.6717.941.3015.67%-450.55%16.50%2/3/2027 (Estimated)
Lincoln National Corporation stock logo
LNC
Lincoln National
$1.18B$16.192.484.641.2016.36%17.02%0.39%N/A
Phillips 66 stock logo
PSX
Phillips 66
$4.40B$31.317.767.140.137.27%33.12%13.04%2/3/2027 (Estimated)

Latest LNC, ABBV, and PSX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Lincoln National Corporation stock logo
LNC
Lincoln National
$1.96$1.72-$0.24$6.77$4.97 billion$5.06 billion
10/30/2026Q3 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.73$3.82+$0.09$2.37$17.32 billion$17.40 billion
10/28/2026Q3 2026
Phillips 66 stock logo
PSX
Phillips 66
$11.73$14.08+$2.35$14.08$44.91 billion$50.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$7.282.57%+6.80%125.30%53 Years
Lincoln National Corporation stock logo
LNC
Lincoln National
$1.804.38%+2.38%11.12%N/A
Phillips 66 stock logo
PSX
Phillips 66
$5.322.20%+5.70%16.99%14 Years

Latest LNC, ABBV, and PSX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/29/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.822.47%1/15/20271/15/20272/16/2027
11/10/2026
Lincoln National Corporation stock logo
LNC
Lincoln National
quarterly$0.454.21%1/11/20271/11/20272/1/2027
10/16/2026
Phillips 66 stock logo
PSX
Phillips 66
quarterly$1.332.07%11/17/202611/17/202612/1/2026
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.44%10/15/202610/15/202611/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.87
0.75
Lincoln National Corporation stock logo
LNC
Lincoln National
0.73
0.25
0.25
Phillips 66 stock logo
PSX
Phillips 66
0.49
1.34
1.04

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Lincoln National Corporation stock logo
LNC
Lincoln National
72.81%
Phillips 66 stock logo
PSX
Phillips 66
76.93%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
Lincoln National Corporation stock logo
LNC
Lincoln National
1.03%
Phillips 66 stock logo
PSX
Phillips 66
0.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
Lincoln National Corporation stock logo
LNC
Lincoln National
9,423190.42 million188.46 millionOptionable
Phillips 66 stock logo
PSX
Phillips 66
12,600390.07 million388.51 millionOptionable

Recent News About These Companies

What’s Going On With Phillips 66 (PSX)?
Phillips 66 (PSX) - What Are Researchers Thinking About This Stock?
Valero Energy vs. Phillips 66: Which is the Stronger Refining Player?
Esports & Natural Resources Led NTHM Performance in Q3
Phillips 66: Priced For A War Premium The Futures Say Won't Last
4 High-Yield Energy Stocks Retirees Should Buy Before December
Bet on Winning DuPont Analysis & Pick 5 Top Stocks
Phillips 66's Dividend Analysis
Is Chevron Stock Overpriced Versus Its Oil Rivals?
Trading at just 8x P/E with 464% EPS growth: Is Valero a bargain?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$286.14 +2.60 (+0.92%)
As of 03:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Lincoln National stock logo

Lincoln National NYSE:LNC

$39.65 -1.40 (-3.40%)
As of 03:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lincoln National Corporation, through its subsidiaries, operates multiple insurance and retirement businesses in the United States. It operates in four segments: Life Insurance, Annuities, Group Protection, and Retirement Plan Services. The Life Insurance segment provides life insurance products, including term insurance, universal life insurance (UL), indexed universal life insurance, variable universal life insurance (VUL), linked-benefit UL and VUL products, and critical illness and long-term care riders. The Annuities segment offers variable, fixed, and registered index-linked annuities. The Group Protection segment offers group non-medical insurance products consisting of short and long-term disability and statutory disability; paid family medical leave administration and absence management services; term life; dental and vision; and accident, critical illness, and hospital indemnity benefits and services to the employer marketplace through various forms of employee-paid and employer-paid plans. The Retirement Plan Services segment provides employers with retirement plan products and services primarily in the defined contribution retirement plan marketplace; individual and group variable annuities, group fixed annuities, and mutual fund-based programs; and various plan services, including plan recordkeeping, compliance testing, participant education, and trust and custodial services. The company distributes its products through consultants, brokers, planners, agents, financial advisors, third-party administrators, and other intermediaries. Lincoln National Corporation was founded in 1905 and is headquartered in Radnor, Pennsylvania.

Phillips 66 stock logo

Phillips 66 NYSE:PSX

$239.54 -3.17 (-1.30%)
As of 03:53 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Phillips 66 operates as an energy manufacturing and logistics company in the United States, the United Kingdom, Germany, and internationally. It operates through four segments: Midstream, Chemicals, Refining, and Marketing and Specialties (M&S). The Midstream segment transports crude oil and other feedstocks; delivers refined petroleum products to market; provides terminaling and storage services for crude oil and refined petroleum products; transports, stores, fractionates, exports, and markets natural gas liquids; provides other fee-based processing services; and gathers, processes, transports, and markets natural gas. The Chemicals segment produces and markets ethylene and other olefin products; aromatics and styrenics products, such as benzene, cyclohexane, styrene, and polystyrene; and various specialty chemical products, including organosulfur chemicals, solvents, catalysts, and chemicals used in drilling and mining. The Refining segment refines crude oil and other feedstocks into petroleum products, such as gasolines, distillates, aviation, and renewable. The M&S segment purchases for resale and markets refined petroleum products, including gasolines, distillates, and aviation fuels. This segment also manufactures and markets specialty products, such as base oils and lubricants. Phillips 66 was founded in 1875 and is headquartered in Houston, Texas.